Redesign Science
Redesign Science is a computational chemistry company that utilizes its NUVO™ technology platform to simulate biomolecular systems and develop first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™). By combining physics-based atomic-level molecular dynamics with generative AI, the company aims to gain unprecedented control over cellular biology and tackle complex challenges in drug discovery. Their innovative approach positions them at the forefront of early-stage drug development, addressing emerging biological pathways and disease mechanisms with a focus on targeted therapies.
Redesign Science
Redesign Science is a computational chemistry company that utilizes its NUVO™ technology platform to simulate biomolecular systems and develop first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™). By combining physics-based atomic-level molecular dynamics with generative AI, the company aims to gain unprecedented control over cellular biology and tackle complex challenges in drug discovery. Their innovative approach positions them at the forefront of early-stage drug development, addressing emerging biological pathways and disease mechanisms with a focus on targeted therapies.
TL;DR
Founded: 2017
Headquarters: New York City
Focus: Physics-based molecular simulation + generative AI for small-molecule drug discovery
Platform: NUVO
Total disclosed funding: USD 17,000,000
Company Overview
Problem Domain
Early-stage small-molecule drug discovery; targeted modulation of protein interactions.
Founded
2017
Industry
Biotechnology
Funding Track Record
Multiple investors reported in the syndicate
Investor Signal
“Syndicate includes venture investors such as Kaitai Capital, Notation Capital, Collaborative Fund, Preface Ventures, ZhenFund, Third Kind VC, Notation Capital, 5Y Capital, Refactor, Creative Destruction Lab, and others”